Journal
CANCER RESEARCH
Volume 68, Issue 21, Pages 8654-8656Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-1904
Keywords
-
Categories
Funding
- NINDS NIH HHS [R01 NS054085-01A1, R01 NS055089] Funding Source: Medline
Ask authors/readers for more resources
Hypermethylated in cancer-1 (HICI) is a tumor suppressor frequently targeted for promoter hypermethylation in medulloblastoma, an embryonal tumor of the cerebellum. Recently, we showed that HICI is a direct transcriptional repressor of ATOH1, a proneural transcription factor required for normal cerebellar development, as well as for medulloblastoma cell viability. Because demethylating agents can induce reexpression of silenced tumor suppressors, restoring HICI function may present an attractive therapeutic avenue in medulloblastoma by exploiting an apparent addiction to ATOH1. [Cancer Res 2008;68(21):8654-6]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available